Interleukin-23 study in lupus and lung disease
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial looks at a protein called interleukin-23 in people with lupus, especially those who also have lung inflammation (interstitial lung disease). The goal is to understand more about this protein's role and possibly find new ways to help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic lupus erythematosus (SLE, also known as lupus).
- You may or may not have a related lung condition called interstitial lung disease (ILD).
- You do not have other chest or lung problems besides ILD.
- You are not currently taking immune-blocking biologic therapies.
- You are not currently on immunosuppressive drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies people with connective tissue diseases (like lupus or rheumatoid arthritis) who have lung or chest symptoms. It aims to better understand and manage these lung problems, which may help improve your breathing and quality of life.
This study looks at whether certain substances in the blood, such as uric acid, homocysteine, and interleukin-17, are higher in people with lupus-related kidney disease compared to healthy individuals. It aims to find new ways to monitor or understand the condition better.
This study measures a blood protein called IL-33 in people with lupus, including those with kidney involvement (lupus nephritis), to see if it relates to their symptoms. It may help doctors understand lupus better and find new ways to treat it.
This study is gathering information on how well Il-23 inhibitors work and how safe they are for people with ulcerative colitis or Crohn's disease in China. It is a real-world study, meaning it looks at people using these drugs in everyday medical practice.
This study tests whether a new medication that targets immune system inflammation (IL-23) can help people with schizophrenia feel better. Researchers believe this immune approach might reduce symptoms when combined with regular antipsychotic treatment.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
Hear when a new Systemic Lupus Erythematosus Related Interstial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.